Trk 13: CER/Glob Health Econ [
clear filter]
4:00pm EDT
#271: The Things Kids Say: Clinical Outcome Assessments in Pediatric Clinical Trials
Chair 
Associate Director, Pediatric Center of Excellence, Quintiles
Gina Calarco is an Associate Director of Project Management and the Deputy Head of the Pediatric Center of Excellence (PCoE) at Quintiles. Ms Calarco completed her BSN at Saint Luke’s College and MPH from the University of Kansas. She is an affiliate member of the American Academy...
Read More →
Deputy Division Director, Gastroenterology and Inborn Errors Products, OND, CDER, FDA
Andrew E. Mulberg, MD, FAAP, CPI, is Associate Professor of Pediatrics University of Pennsylvania and Professor of Pediatrics at Unviersity of Maryland. He has principally edited a book entitled Pediatric Drug Development: Concepts and Applications published in 2009 and 2013 with...
Read More →
Director, Patient-Centered Outcomes, Adelphi Values
As Director of Patient-Centered Outcomes at Adelphi Values, Diane Turner-Bowker provides senior scientific leadership on the development of COAs for use in medical product development to support regulatory, payer, and communication strategies, as well as for use in clinical practice...
Read More →
Tuesday June 28, 2016 4:00pm - 5:15pm EDT
103A
Pennsylvania Convention Center 1101 Arch Street, Philadelphia, PA 19107 USA
10:30am EDT
#322: Real-World Evidence in Drug Development: Creating the Right Environment for Enhanced Pre-Launch Evidence
Chair PS
Project Manager, University Medical Centre Utrecht
Pieter Stolk, PhD, was trained as a pharmacist with a PhD from Utrecht University. Pieter is interested in all aspects of medicines regulation and policy (with a focus on marketing authorisation and HTA of medicines). He has been involved in several EU public private partnerships...
Read More → CC
Head of Real World Data Strategy and Partnerships, Sanofi
Chris graduated from Oxford University with a degree in Biochemistry. He qualified as a chartered accountant with Ernst & Young in London and completed a MSc in Health Economics at City University, London. He has led health outcomes research teams at Eli Lilly and GSK, and in his...
Read More → 
Global Head of Public Policy, Global Corporate Affairs, Eli Lilly and Company, United States
Gregory Daniel, PhD, MPH, is the Global Head of Public Policy at Eli Lilly & Company in Washington, D.C. Greg is also on the board of directors for the Innovation in Value Initiative (IVI), adjunct associate professor at the UNC Eshelman School of Pharmacy, and Visiting Expert at...
Read More →
Deputy Director and Clinical Professor, Duke-Margolis Center For Health Policy
Gregory Daniel, PhD, MPH is the Deputy Director of the Duke-Robert J. Margolis, MD Center for Health Policy and a Clinical Professor in Duke's Fuqua School of Business. He directs the DC-based office of the Center leading its pharmaceutical and medical device policy portfolio, and...
Read More →PS
Program Manager, Escher, the Lygature Platform For Regulatory Innovation
Pieter Stolk, PhD, was trained as a pharmacist with a PhD from Utrecht University. Pieter is interested in all aspects of medicines regulation and policy (with a focus on marketing authorisation and HTA of medicines). He has been involved in several EU public private partnerships...
Read More →
Wednesday June 29, 2016 10:30am - 11:30am EDT
107AB
Pennsylvania Convention Center 1101 Arch Street, Philadelphia, PA 19107 USA
